Table 2.
The expression of LAMC1 tested by IHC in 8 normal brain tissue and 76 astrocytoma
| Clinical relevance | No. of patients | IRS of LAMC1, mean±SD | P |
|---|---|---|---|
| Pathologic Grade | |||
| NBT | 8 | 1.12±0.68 | <0.001 |
| WHOⅠ | 10 | 2.02±1.02 | |
| WHOⅡ | 19 | 2.98±1.56 | |
| WHOⅢ | 22 | 4.23±1.89 | |
| WHOⅣ | 25 | 5.24±2.21 | |
| Age | |||
| <39ys | 32 | 3.64±1.68 | 0.173 |
| ≥39ys | 44 | 4.19±1.75 | |
| Sex | |||
| Male | 35 | 3.72±1.81 | 0.274 |
| Female | 41 | 4.16±1.67 | |
| Tumor size | |||
| <35cm | 44 | 3.75±1.89 | 0.245 |
| ≥35cm | 32 | 4.25±1.76 | |
| IDH1 mutation | |||
| Mutation | 23 | 4.38±1.94 | 0.141 |
| Wildtype | 53 | 3.77±1.50 | |
| MGMT promoter methylation | |||
| Methylated | 30 | 3.51±1.97 | 0.128 |
| Not methylated | 46 | 4.25±2.10 |
Notes: The results of immunohistochemistry (IHC) detection indicated that high LAMC1 expression was significantly associated with glioma WHO grade (P<0.05) but not with patient sex, age, or tumor size and IDH1 mutation or MGMT promoter methylation.
Abbreviations: IHC, immunohistochemistry; IRS, immunohistochemistry scores; NBT, normal brain tissue; WHO, World Health Organization.